585 related articles for article (PubMed ID: 17600122)
41. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
[TBL] [Abstract][Full Text] [Related]
42. Knockdown of vimentin reduces mesenchymal phenotype of cholangiocytes in the Mdr2
Zhou T; Kyritsi K; Wu N; Francis H; Yang Z; Chen L; O'Brien A; Kennedy L; Ceci L; Meadows V; Kusumanchi P; Wu C; Baiocchi L; Skill NJ; Saxena R; Sybenga A; Xie L; Liangpunsakul S; Meng F; Alpini G; Glaser S
EBioMedicine; 2019 Oct; 48():130-142. PubMed ID: 31522982
[TBL] [Abstract][Full Text] [Related]
43. Impact of experimental colitis on hepatobiliary transporter expression and bile duct injury in mice.
Jahnel J; Fickert P; Langner C; Högenauer C; Silbert D; Gumhold J; Fuchsbichler A; Trauner M
Liver Int; 2009 Oct; 29(9):1316-25. PubMed ID: 19558576
[TBL] [Abstract][Full Text] [Related]
44. Colesevelam attenuates cholestatic liver and bile duct injury in
Fuchs CD; Paumgartner G; Mlitz V; Kunczer V; Halilbasic E; Leditznig N; Wahlström A; Ståhlman M; Thüringer A; Kashofer K; Stojakovic T; Marschall HU; Trauner M
Gut; 2018 Sep; 67(9):1683-1691. PubMed ID: 29636383
[TBL] [Abstract][Full Text] [Related]
45. Fibrin deposition following bile duct injury limits fibrosis through an αMβ2-dependent mechanism.
Joshi N; Kopec AK; Ray JL; Cline-Fedewa H; Nawabi A; Schmitt T; Nault R; Zacharewski TR; Rockwell CE; Flick MJ; Luyendyk JP
Blood; 2016 Jun; 127(22):2751-62. PubMed ID: 26921287
[TBL] [Abstract][Full Text] [Related]
46. Chronic cholestatic liver diseases: clues from histopathology for pathogenesis.
Pollheimer MJ; Fickert P; Stieger B
Mol Aspects Med; 2014 Jun; 37():35-56. PubMed ID: 24141039
[TBL] [Abstract][Full Text] [Related]
47. Knockout of the primary sclerosing cholangitis-risk gene Fut2 causes liver disease in mice.
Maroni L; Hohenester SD; van de Graaf SFJ; Tolenaars D; van Lienden K; Verheij J; Marzioni M; Karlsen TH; Oude Elferink RPJ; Beuers U
Hepatology; 2017 Aug; 66(2):542-554. PubMed ID: 28056490
[TBL] [Abstract][Full Text] [Related]
48. Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice.
Zhou M; Learned RM; Rossi SJ; DePaoli AM; Tian H; Ling L
Hepatology; 2016 Mar; 63(3):914-29. PubMed ID: 26418580
[TBL] [Abstract][Full Text] [Related]
49. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver.
Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Pojer C; Zenz R; Lammert F; Stieger B; Meier PJ; Zatloukal K; Denk H; Trauner M
Gastroenterology; 2001 Jul; 121(1):170-83. PubMed ID: 11438506
[TBL] [Abstract][Full Text] [Related]
50. Biliary tract instillation of a SMAC mimetic induces TRAIL-dependent acute sclerosing cholangitis-like injury in mice.
Guicciardi ME; Krishnan A; Bronk SF; Hirsova P; Griffith TS; Gores GJ
Cell Death Dis; 2017 Jan; 8(1):e2535. PubMed ID: 28055006
[TBL] [Abstract][Full Text] [Related]
51. Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2
Fuchs CD; Dixon ED; Hendrikx T; Mlitz V; Wahlström A; Ståhlman M; Scharnagl H; Stojakovic T; Binder CJ; Marschall HU; Trauner M
Hepatol Commun; 2022 Sep; 6(9):2368-2378. PubMed ID: 35691019
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice.
Jones H; Hargrove L; Kennedy L; Meng F; Graf-Eaton A; Owens J; Alpini G; Johnson C; Bernuzzi F; Demieville J; DeMorrow S; Invernizzi P; Francis H
Hepatology; 2016 Oct; 64(4):1202-1216. PubMed ID: 27351144
[TBL] [Abstract][Full Text] [Related]
53. Activation of the developmental pathway neurogenin-3/microRNA-7a regulates cholangiocyte proliferation in response to injury.
Marzioni M; Agostinelli L; Candelaresi C; Saccomanno S; De Minicis S; Maroni L; Mingarelli E; Rychlicki C; Trozzi L; Banales JM; Benedetti A; Baroni GS
Hepatology; 2014 Oct; 60(4):1324-35. PubMed ID: 24925797
[TBL] [Abstract][Full Text] [Related]
54. Dose-dependent effects of alpha-naphthylisothiocyanate disconnect biliary fibrosis from hepatocellular necrosis.
Joshi N; Ray JL; Kopec AK; Luyendyk JP
J Biochem Mol Toxicol; 2017 Jan; 31(1):1-7. PubMed ID: 27605088
[TBL] [Abstract][Full Text] [Related]
55. Nrf2 Ameliorates DDC-Induced Sclerosing Cholangitis and Biliary Fibrosis and Improves the Regenerative Capacity of the Liver.
Fragoulis A; Schenkel J; Herzog M; Schellenberg T; Jahr H; Pufe T; Trautwein C; Kensler TW; Streetz KL; Wruck CJ
Toxicol Sci; 2019 Jun; 169(2):485-498. PubMed ID: 30825315
[TBL] [Abstract][Full Text] [Related]
56. Interleukin 2 Promotes Hepatic Regulatory T Cell Responses and Protects From Biliary Fibrosis in Murine Sclerosing Cholangitis.
Taylor AE; Carey AN; Kudira R; Lages CS; Shi T; Lam S; Karns R; Simmons J; Shanmukhappa K; Almanan M; Chougnet CA; Miethke AG
Hepatology; 2018 Nov; 68(5):1905-1921. PubMed ID: 29698570
[TBL] [Abstract][Full Text] [Related]
57. The Cholangiocyte Adenosine-IL-6 Axis Regulates Survival During Biliary Cirrhosis.
Lavoie EG; Fausther M; Goree JR; Dranoff JA
Gene Expr; 2017 Nov; 17(4):327-340. PubMed ID: 28893353
[TBL] [Abstract][Full Text] [Related]
58. Hepatobiliary transporter expression in intercellular adhesion molecule 1 knockout and Fas receptor-deficient mice after common bile duct ligation is independent of the degree of inflammation and oxidative stress.
Wagner M; Zollner G; Fickert P; Gumhold J; Silbert D; Fuchsbichler A; Gujral JS; Zatloukal K; Denk H; Jaeschke H; Trauner M
Drug Metab Dispos; 2007 Sep; 35(9):1694-9. PubMed ID: 17576807
[TBL] [Abstract][Full Text] [Related]
59. Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis.
Hisamoto S; Shimoda S; Harada K; Iwasaka S; Onohara S; Chong Y; Nakamura M; Bekki Y; Yoshizumi T; Ikegami T; Maehara Y; He XS; Gershwin ME; Akashi K
J Autoimmun; 2016 Dec; 75():150-160. PubMed ID: 27592379
[TBL] [Abstract][Full Text] [Related]
60. Patient-Derived Organoids from Human Bile: An In Vitro Method to Study Cholangiopathies.
Soroka CJ; Assis DN; Boyer JL
Methods Mol Biol; 2019; 1981():363-372. PubMed ID: 31016667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
